Skip to main content
Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
106.90
-0.61 (-0.57%)
At close: Jun 27, 2025, 4:00 PM
106.50
-0.40 (-0.37%)
After-hours: Jun 27, 2025, 6:24 PM EDT

Jazz Pharmaceuticals Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Neuroscience
2.72B 2.70B 2.66B 2.63B 2.64B 2.71B 2.76B 2.80B
Neuroscience Growth
3.25% -0.35% -3.68% -5.92% -5.85% -1.92% 1.99% 5.89%
Oncology
1.08B 1.11B 1.09B 1.07B 1.04B 1.02B 965.36M 928.30M
Oncology Growth
3.77% 9.47% 13.26% 15.16% 15.23% 16.18% 12.64% 13.42%

Oncology Revenue Breakdown
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Rylaze Enrylaze
402.33M 410.85M 411.11M 417.19M 411.05M 394.23M 373.45M 342.11M
Rylaze Enrylaze Growth
-2.12% 4.22% 10.08% 21.95% 31.17% 39.97% 40.58% 60.76%
Zepzelca
308.25M 320.32M 316.00M 308.15M 297.45M 289.53M 287.49M 279.82M
Zepzelca Growth
3.63% 10.63% 9.92% 10.13% 7.09% 7.27% 9.40% 5.92%
Defitellio Defibtrotide
209.55M 216.57M 210.00M 191.91M 192.60M 184.00M 173.57M 175.29M
Defitellio Defibtrotide Growth
8.80% 17.70% 20.99% 9.48% 4.74% -5.30% -11.51% -14.24%
Vyxeos
160.12M 162.60M 156.26M 151.77M 142.82M 147.50M 130.85M 131.09M
Vyxeos Growth
12.11% 10.24% 19.42% 15.78% 9.09% 15.25% -1.23% -4.38%

Neroscience Revenue Breakdown
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Xywav
1.50B 1.47B 1.41B 1.35B 1.31B 1.27B 1.22B 1.14B
Xywav Growth
14.67% 15.73% 15.77% 18.46% 24.80% 32.82% 41.60% 50.85%
Epidiolex
991.44M 972.42M 938.00M 900.15M 855.28M 845.47M 811.84M 794.35M
Epidiolex Growth
15.92% 15.02% 15.54% 13.32% 11.45% 14.81% 12.26% 15.57%
Xyrem
206.83M 233.82M 291.25M 358.24M 455.83M 569.73M 710.51M 841.43M
Xyrem Growth
-54.63% -58.96% -59.01% -57.42% -52.07% -44.17% -33.08% -24.40%
Sativex
21.55M 18.88M 18.84M 18.88M 15.31M 19.67M 19.25M 17.85M
Sativex Growth
40.80% -4.02% -2.13% 5.81% -20.21% 16.90% 14.92% -9.09%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.